Aktis Oncology Inc. (AKTS)
NASDAQ: AKTSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
AKTS stock chart
Technical analysisKey statistics
All statistics- Market cap
- $901.14M
- EPS (TTM)
- -$1.80
- Dividend yield
- None
- 52-week range
- 13.96 – 34.19
- Day range
- 16.00 – 16.74
- Volume / Avg
- 374.79K / 408.46K
- Beta
- —
- Shares outstanding
- 53.93M
52-week range
AKTS stock today
Shares of Aktis Oncology (AKTS) finished lower on Nov 20 at $16.15, a drop of 1.52% or $0.25 per share, versus the S&P 500's 3.70% decline. Shares are 52.8% below their 52-week high of $34.19, set on Jun 30, 2026 and 15.7% above the 52-week low of $13.96, near the bottom of the past year's range. Aktis Oncology has posted a net loss over the last twelve months (EPS of -$1.80), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Aktis Oncology
Company profileAktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers. The company's lead product candidate includes [225Ac]Ac-AKY-1189, a miniprotein radioconjugate platform which is in ongoing Phase 1b clinical trial for the treatment of Nectin-4 expressing solid tumors, including locally advanced or metastatic urothelial cancer, breast cancer, NSCLC, colorectal cancer and cervical cancer; and [225Ac]Ac-AKY-2519 to deliver 225Ac to B7-H3 (CD276) expressing tumors, including prostate, lung and other solid tumors. It has license and collaboration agreements with Protein Innovation, Inc., TRIUMF Innovations, Inc., and Eli Lilly.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Matthew Roden Ph.D.
- Headquarters
- Boston, MA
- Employees
- 79
- IPO year
- 2026
- Website
- aktisoncology.com
Analyst forecast
ForecastConsensus (10 analysts)
strong_buy
Avg. price target
$35.88+122.17%
- Strong buy 1
- Buy 9
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 12, 2026
- EPS actual vs est.
- $-0.54 vs $-0.47
- Surprise
- -14.89%
AKTS news
All AKTS newsAktis Oncology peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| SVRASavara Inc. | 4.26 | -18.23% | $939.86M | vs AKTS |
| MLTXMoonLake Immunotherapeutics Class A | 11.07 | +0.36% | $942.13M | vs AKTS |
| CYRXCryoPort Inc. | 19.05 | -2.56% | $964.87M | vs AKTS |
| SPTXSeaport Therapeutics Inc. | 18.05 | -1.47% | $966.23M | vs AKTS |
| LTGOLatigo Biotherapeutics Inc. | 13.00 | -1.81% | $861.89M | vs AKTS |
| MTRIMentari Therapeutics Inc. | 14.70 | -3.57% | $856.94M | vs AKTS |
| OMEROmeros Corporation | 13.21 | -5.71% | $983.66M | vs AKTS |
| PHARPharming Group N.V. ADS | 11.54 | -5.10% | $816.78M | vs AKTS |
Indexes, lists and sector
Aktis Oncology stock FAQ
What is Aktis Oncology's stock price today?
AKTS last traded at $16.15 as of Nov 20, 4:00 PM EST, down 1.52% on the day. Prices are delayed at least 15 minutes.
Who is Aktis Oncology's CEO?
Dr. Matthew Roden Ph.D. is the chief executive officer of Aktis Oncology Inc., which has about 79 employees.
What is the AKTS 52-week high?
The 52-week high for AKTS is $34.19 and the 52-week low is $13.96. The stock is currently 52.8% below its high.